Gilead Sciences said Monday it will charge $2,340 for usual treatment of Remdesivir, a drug that is used to shorten recovery time for severely ill COVID-19 patients. However, critics have called the price an outrage because of the amount taxpayers invested toward its development. The drug maker said Monday that price would be for people covered by government health programs in the United States and other developed countries. For patients with private health insurance, the price would be $3,120. The amount that patients actually pay themselves could be lower. Gilead’s chief executive Dan O’Day told the Associated Press, we’re in uncharted territory with pricing a new medicine, a novel medicine, in a pandemic.